Skip to main content
SpringerLink
Log in

Efficacy comparison of nanoniosomal and pegylated nanoniosomal Cisplatin on A172 cell line

  • Original Article
  • Biomaterials
  • Published:
Tissue Engineering and Regenerative Medicine Aims and scope

Abstract

In this study, Cisplatin was loaded into nanoniosom and pegylated nanoniosom employing reverse phase evaporation method. Span 60, cholesterol and Cisplatin were combined together at certain concentrations in this method. This study reports the efficacy of nanoniosome Cisplatin and pegylated nanoniosome Cisplatin on brain cancer (A172) cell line. All of the results are presented from three independent tests. The obtained results showed that the stability of prepared formulation was increased by pegylation. Encapsulation efficiency and loading efficiency of Cisplatin in pegylated and non-pegylated niosomal formulations were estimated 48.2±2.05%, 43.6±4.59%, 4.38±0.28%, 4.36±0.08%, respectively. The average diameters of pegylated and non-pegylated nanoparticles of niosomes were determined by Zeta sizer which was 205.5±4.60 nm and 242.1±5.10 nm, respectively. The release of drug was studied by dialysis method. The amounts of drug released from pegylated and non-pegylated nanoniosomes were calculated 82.73±1.36% and 97.53±0.55% during 48 hr, respectively. The toxicity of formulated Cisplatin was studied by MTT assay and the results revealed that the cytotoxicity effect of pegylated nanoniosomal Cisplatin was more than nanoniosomal Cisplatin. The IC50 for nanoniosomal Cisplatin was estimated 123.2±0.98 μg/mL while IC50 for pegylated nanoniosomal formulation was calculated 79.8±1.14 μg/mL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. G Jianfeng, B Ludovic, MS Declan, et al., Can Non-viral Technologies Knockdown the Barriers to Sirna Delivery and Achieve the Next Generation Of Cancer Therapeutics? Biotechnol Adv, 29, 402 (2011).

    Article  Google Scholar 

  2. MV Blagosklonny, A Node Between Proliferation, Apoptosis and Growth Arrest, Bioessays, 21, 704 (1999).

    Article  PubMed  CAS  Google Scholar 

  3. LM DeAngelis, Brain tumors, N Engl J Med, 344, 114 (2001).

    Article  PubMed  CAS  Google Scholar 

  4. PL Kornblith, M Walker, Chemotherapy for malignant gliomas, J Neurosurg, 68, 1 (1998).

    Article  Google Scholar 

  5. DF Nelson, JS Nelson, DR Davis, et al., Survival and prognosis of patients with astrocytoma with atypical or anaplastic features, J Neuorooncol, 3, 99 (1985).

    Article  CAS  Google Scholar 

  6. American Brain Tumor Assiciation. http://www.abta.org.

  7. SH Giordano, GN Hortobagyi, Inflammatory breast cancer: clinical progress and the main problems that must be addressed, Breast Cancer Res, 5, 284 (2003).

    Article  PubMed  PubMed Central  Google Scholar 

  8. G Giaccone, Clinical perspectives on platinum resistance, Drugs, 59, 9 (2000).

    Article  PubMed  CAS  Google Scholar 

  9. RL Juliano, Drug delivery systems, characteristic and biomedical applications, New York: Oxford University Press (1980).

    Google Scholar 

  10. KB Makeshwar, SR Wasanka, Niosome: a Novel Drug Delivery System, Asian J Pharm, 3, 16 (2013).

    Google Scholar 

  11. C Marianecci, L Marzio, F Rinaldi, et al., Niosomes from 80s to present: The state of the art, Adv Colloid Interface Sci, 205C, 187 (2013).

    Google Scholar 

  12. AJ Baillie, AT Florence, LR Hume, et al., Rogerson. The preparation and properties of niosomes-non-ionic surfactant vesicles, J Pharm Pharmacol, 37, 863 (1985).

    Article  PubMed  CAS  Google Scholar 

  13. SD Pawar, RG Pawar, PP Kodag, et al., Niosome: An Unique Drug Delivery System, IJBPAS, 1, 406 (2012).

    CAS  Google Scholar 

  14. MR Mozafari, Nanocarrier Technologies: Frontiers of Nanotherapy. Michigan: Springer (2006).

    Book  Google Scholar 

  15. G Christiane, W Jörg, Z Andreas, Recombinant virus like particles as drug delivery system, Curr Pharm Biotechnol, 6, 49 (2005).

    Google Scholar 

  16. Z Li, J Chen, W Sun, et al., Investigation of archaeosomes as carriers for oral delivery of peptides, BiochemBiophys Res Commun, 394, 412 (2010).

    Article  CAS  Google Scholar 

  17. G Cortesina, A De Stefani, A Giovarelli, et al., Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically, Cancer, 62, 1482 (1988).

    Article  Google Scholar 

  18. JY Fang, CT Hong, WT Chiu, et al., Effect of Liposomes and niosomes on skin permeation of enoxacin, Int J Pharm, 219, 61 (2001).

    Article  PubMed  CAS  Google Scholar 

  19. A Nasir, SL Harikumar, K Amanpreet, Niosomes: an Excellent tool for drug delivery, IJRPC, 2, 479 (2012).

    Google Scholar 

  20. D Cosco, D Paolino, R Muzzalupo, et al., Novel PEG-coated niosomes based on bola-surfactant as drug carriers for 5- fluorouracil, Biomed Microdevices, 11, 1115 (2009).

    Article  PubMed  CAS  Google Scholar 

  21. S Ramachandran, AP Quist, S Kumar, et al., Cisplatin nanoliposomes for cancer therapy: AFM and fluorescence imaging of cisplatin encapsulation, stability, cellular uptake, and toxicity, Langmuir, 12, 8156 (2006).

    Article  Google Scholar 

  22. SK Bagherpour Doun, SE Alavi, M Koohi Moftakhari Esfahani, et al., Efficacy of Cisplatin-loaded poly butyl cyanoacrylate nanoparticles on the ovarian cancer: an in vitro study, Tumour Biol, (2014). DOI 10.1007/s13277-014-1996-8

    Google Scholar 

  23. N Dadgar, M Koohi Moftakhari Esfahani, S Torabi, et al., Effects of Nanoliposomal and Pegylated Nanoliposomal Artemisinin in Treatment of Breast Cancer, Ind J Clin Biochem, (2013). DOI 10.1007/s12291-013-0389-x

    Google Scholar 

  24. MR Prausnitz, S Mitragotri, R Langer, Current status and future potential of transdermal drug delivery, Nat Rev Drug Discov, 3, 115 (2004).

    Article  PubMed  CAS  Google Scholar 

  25. RM Mainardes, LP Silva, Drug delivery systems: past, present, and future, Curr Drug Targets, 5, 449 (2004).

    Article  PubMed  CAS  Google Scholar 

  26. G Orive, RM Hernández, A Rodríguez Gascón, et al., Drug delivery in biotechnology: present and future, Curr Opin Biotechnol, 14, 659 (2003).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Chemical Engineering, Science and Research Branch, Islamic Azad University, Tehran, Iran

    Mahrokh Babaei, Mehdi Ardjmand, Azim Akbarzadeh & Aliakbar Seyfkordi

Authors
  1. Mahrokh Babaei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mehdi Ardjmand
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Azim Akbarzadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Aliakbar Seyfkordi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Mehdi Ardjmand or Azim Akbarzadeh.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Babaei, M., Ardjmand, M., Akbarzadeh, A. et al. Efficacy comparison of nanoniosomal and pegylated nanoniosomal Cisplatin on A172 cell line. Tissue Eng Regen Med 11, 350–354 (2014). https://doi.org/10.1007/s13770-014-0024-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13770-014-0024-9

Key words

Search

Navigation